3/13
04:42 pm
cadl
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
3/13
04:15 pm
cadl
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Low
Report
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
2/28
07:07 pm
cadl
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]
High
Report
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. [Yahoo! Finance]
2/26
12:29 pm
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $20.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $20.00 to $25.00. They now have a "buy" rating on the stock.
2/26
08:00 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
2/25
09:34 am
cadl
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer [Yahoo! Finance]
2/25
08:00 am
cadl
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
High
Report
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
2/20
07:13 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $25.00 price target on the stock.
High
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $25.00 price target on the stock.
2/19
07:06 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $20.00 price target on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $20.00 price target on the stock.
2/7
08:28 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $15.00 price target on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $15.00 price target on the stock.
1/13
08:00 am
cadl
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
Low
Report
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
12/18
08:07 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $11.00.
Low
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $11.00.
12/16
04:01 pm
cadl
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Medium
Report
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
12/12
11:00 pm
cadl
Candel Therapeutics Announces Pricing of Public Offering
Medium
Report
Candel Therapeutics Announces Pricing of Public Offering
12/12
04:51 pm
cadl
Candel Therapeutics Announces $80 Million Proposed Public Offering
High
Report
Candel Therapeutics Announces $80 Million Proposed Public Offering